-
PDK4-IN-1 Hydrochloride: Mechanism and Uses
2026-08-25
PDK4-IN-1 hydrochloride is a selective pyruvate dehydrogenase kinase 4 inhibitor for research on PDH activation, mitochondrial energy metabolism modulation, and metabolic disease models. Product information reports nanomolar biochemical potency, oral activity, selectivity over PDK1–3, and use in in vitro and animal workflows.
-
Nerve-Dependent HDAC1 in Axolotl Limb Regeneration
2026-08-24
Wang and colleagues show that nerve signals regulate HDAC1 expression in the wound epidermis and that this epigenetic response is required for axolotl blastema formation and limb regeneration. Pharmacological inhibition, denervation, and nerve-factor rescue experiments connect neural input to local HDAC activity, providing a mechanistic framework for studying regeneration rather than treating HDACs as generic downstream markers.
-
GGFG Peptide: Linker Design for Translation
2026-08-23
Gly-Gly-Phe-Gly is more than a flexible spacer: it is a defined design element for testing how linker architecture, local chemistry, and analytical controls shape translational bioconjugation.
-
Adiponectin, TLR4, and Cognitive Deficits After Splenectomy
2026-08-22
This reference study identifies adiponectin as a potential modulator of splenectomy-associated cognitive impairment in aged rats and links its effects to reduced TLR4/MyD88/NF-κB signaling, oxidative stress, and microglial inflammation. Its pharmacological design strengthens the case for pathway involvement, while the pretreatment model and animal-specific evidence define important limits for clinical translation.
-
10-Gingerol, TFEB, and Ferroptosis in NSCLC
2026-08-21
The reference study identifies a lysosome-centered mechanism by which 10-gingerol induces ferroptosis in non-small cell lung cancer: TFEB activation promotes lysosomal degradation of NRF2, weakening the xCT/GPX4 antioxidant system. Its findings connect lysosomal regulation, iron-dependent lipid damage, and tumor suppression, while also highlighting the need to distinguish ferroptosis from caspase-dependent apoptosis in experimental design.
-
Light-Inducible RNA Release for Regulated Gene Therapy
2026-08-21
The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic protein production at the translation stage rather than through transcriptional regulation. In mouse models, LIRP-enabled AAV systems used daylight or blue light to activate treatment and darkness or selective filtering to interrupt it, supporting more controllable gene therapy for metabolic and retinal disease.
-
Metabolic Intervention Sensitizes Ferroptosis/Cuproptosis
2026-08-20
This Chemical Engineering Journal study introduces SCu/L, a copper–tannic acid network/liposome system carrying STF-31 to inhibit glycolysis and compensatory NAD+ metabolism. The resulting metabolic stress increases tumor-cell susceptibility to ferroptosis and cuproptosis while reshaping the tumor immune microenvironment and strengthening antitumor immunity.
-
Self-Assembling EVMPs for Extrahepatic mRNA Delivery
2026-08-20
The reference study introduces a bottom-up enveloped virus-mimicking particle (EVMP) that combines a self-assembling peptide with programmable phospholipid envelopes to target mRNA beyond the liver. Its lung-targeted formulation transfected major lung cell populations and delivered IL-12 mRNA with tumor-suppressive activity in a metastatic lung tumor model, while showing potential for repeat dosing and further safety evaluation.
-
Exosomal HMGB1 in Lupus Nephritis Endothelial Injury
2026-08-19
The reference study identifies podocyte-derived exosomes as a disease-relevant route for delivering HMGB1 to glomerular endothelial cells in lupus nephritis. By combining pharmacological inhibition, exosome depletion, cargo knockdown, and mouse experiments, it links exosomal HMGB1 to endothelial injury through TRIM27 regulation and provides a framework for testing vesicle-mediated kidney pathology.
-
CFDA SE Cell Tracer Kit: Practical Guide
2026-08-19
The CFDA SE Cell Tracer Kit provides persistent fluorescent labeling for cell lineage tracing, cell proliferation studies, and longitudinal cell tracking. It is appropriate when covalent, multi-day labeling is needed, but not when the experiment requires reversible or short-term physiological labeling.
-
Reelin–Apoer2–SFK Signaling in Ketamine Action
2026-08-18
This PNAS study identifies Reelin–Apoer2–Src family kinase signaling as a permissive requirement for ketamine-induced hippocampal synaptic plasticity and behavioral effects. Its combination of genetic deletions, pathway inhibition, electrophysiology, molecular analysis, and behavioral testing provides a mechanistic framework for understanding why some treatment-resistant depression models may fail to respond to ketamine.
-
KR-12 Human Antimicrobial Peptide: Applied Workflows
2026-08-18
KR-12 is a compact LL-37-derived tool for membrane-focused antimicrobial, biofilm, LPS, and inflammation studies. This workflow emphasizes strain-aware dosing, TFA-salt handling, and copper-sensitive assay design so researchers can separate genuine biology from formulation or metal-binding artifacts.
-
RG7388: Applied MDM2 Antagonist Workflows
2026-08-17
RG7388 connects biochemical disruption of the p53-MDM2 interaction with practical cell-based apoptosis and combination-treatment workflows. This guide shows how to select responsive models, control compound handling, interpret p53 pathway activation, and use the MDM1-p53 findings from colorectal cancer research without overextending the evidence.
-
AICAR: AMPK Activation for Metabolic Research
2026-08-16
AICAR is a cell-permeable pharmacological tool for studying AMPK-dependent energy metabolism regulation, inflammatory signaling, and cellular stress protection. Its intracellular AMP-mimetic activity supports metabolic research, but concentration, cell type, and pathway-specific controls are essential for interpretation.
-
(S)-Mephenytoin in CYP2C19 Organoid Assays
2026-08-15
(S)-Mephenytoin provides a practical CYP2C19 substrate for connecting human intestinal organoid biology with oxidative drug metabolism. This workflow combines parent-drug depletion, 4-hydroxy metabolite formation, barrier assessment, and controls that help distinguish enzyme activity from permeability or culture artifacts.